DBV Technologies | DBVT - 销售和管理费用



金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 727.7M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


销售和管理费用 更改 日
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
DBV Technologies USD 3.63M 3.18M 2025-09
Esperion Therapeutics USD 39.42M 456K 2025-12
Galectin Therapeutics USD 1.48M 110K 2024-06
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Insmed USD 247.26M 34.78M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 156.6M 34M 2026-03